Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Al Sifri, Saud N ^a   Almahmeed, Wael ^b   Azar, Sami ^c   Okkeh, Osama ^d   Bramlage, Peter ^e   Jünger, Claus ^f,g   Halawa, Islam ^h   Ambegaonkar, Baishali ⁱ   Wajih, Sameh ^j   Brudi, Philippe ⁱ  

^a AL HADA ARMED FORCES HOSPITAL   (Saudi Arabia)

^b SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d Istishari Hospital Amman   (Jordan)

^e Institut fur Pharmakologie und Praventive Medizin   (Germany)

^f Institut fuer Herzinfarktforschung   (Germany)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h Medical Imaging Department   (Saudi Arabia)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j University of the United Arab Emirates   (United Arab Emirates)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; JORDAN; LEBANON; LIFESTYLE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PATIENT CODING; PREVALENCE; SAUDI ARABIA; TREATMENT DURATION; UNITED ARAB EMIRATES;

AGED; COMORBIDITY; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; MIDDLE EAST; PREVALENCE; RISK FACTORS;

EID: 84896962894     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084350     Document Type: Article

References (26)

1. Organization WH (2012). Cardiovascular diseases (CVDs) Fact sheet no. 317.
2. Ramahi TM (2010) Cardiovascular disease in the Asia Middle East region: global trends and local implications. Asia Pac J Public Health 22: 83S-89S. doi:10.1177/1010539510373034. PubMed: 20566538.
3. Organization WH (2011) Saudi Arabia. World Health Organization - NCD Country Profiles.
4. Organization WH (2011) Lebanon. World Health Organization - NCD Country Profiles.
5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278. doi:10.1016/S0140-6736(05)67394-1. PubMed: 16214597.
6. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM et al. (2006) Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368: 919-928. doi:10.1016/S0140-6736(06)69292-1. PubMed: 16962881. (Pubitemid 44331360)
7. Kearney PM, Blackwell L, Collins R, Keech A, Simes J et al. (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117-125. doi:10.1016/S0140-6736(08)60104-X. PubMed: 18191683.
8. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I et al. (2004) Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164: 1427-1436. doi:10.1001/archinte.164.13.1427. PubMed: 15249352. (Pubitemid 38937854)
9. Cziraky MJ, Watson KE, Talbert RL (2008) Targeting low HDLcholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 14: 28-S30; quiz: 19891279.
10. Nesto RW (2005) Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5: 379-387. doi:10.2165/00129784-200505060-00005. PubMed: 16259526.
11. Kotseva K (2011). Lessons from EUROASPIRE i, II and III Surveys. Heart Metab 50: 32-35.
12. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D (2008) Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 197: 710-717. doi:10.1016/j.atherosclerosis.2007.07.004. PubMed: 17765905. (Pubitemid 351417868)
13. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, et al. (2009) Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373: 929-940.
14. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z et al. (2012) European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) : The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of Nine Societies and by Invited Experts). Int J Behav Med.
15. Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR et al. (2012) Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 19: 221-230. doi:10.1177/1741826711400545. PubMed: 21450578.
16. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239. doi:10.1161/01.CIR.0000133317.49796.0E. PubMed: 15249516. (Pubitemid 38924592)
17. Roberts WC (1997) The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 80: 106-107. doi:10.1016/S0002-9149(97)00298-1. PubMed: 9205036.
18. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR et al. (2011) ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217: 3-46. doi:10.1016/j.atherosclerosis.2011.06.028. PubMed: 21882396.
19. Moss M, Wellman DA, Cotsonis GA (2003) An appraisal of multivariable logistic models in the pulmonary and critical care literature. Chest 123: 923-928. doi:10.1378/chest.123.3.923. PubMed: 12628895. (Pubitemid 36315510)
20. Eber B, Lautsch D, Fauer C, Drexel H, Pfeiffer KP et al. (2012) Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. Curr Med Res Opin 28: 1447-1454. doi:10.1185/03007995.2012.717919. PubMed: 22856551.
21. Bandgar TR, Faruqui AA (2011) Managing dyslipidaemia: evolving role of combination therapy. J Indian Med Assoc 109: 549-552. PubMed: 22315861.
22. Ito MK (2012) Dyslipidemia: management using optimal lipid-lowering therapy. Ann Pharmacother 46: 1368-1381. doi:10.1345/aph.1R127. PubMed: 23032652.
23. Boumedjout H (2012) Cardiovascular diseases on the increase in Arab states. Nature Middle East.
24. Al-Baghli NA, Al-Ghamdi AJ, Al-Turki KA, El-Zubaier AG, Al-Mostafa BA, et al. (2010) Awareness of cardiovascular disease in eastern Saudi Arabia. J Family Community Med 17: 15-21
25. Shara NM (2010) Cardiovascular disease in Middle Eastern women. Nutr Metab Cardiovasc Dis 20: 412-418. doi:10.1016/j.numecd.2010.01.013. PubMed: 20554171.
26. Goff DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS et al. (2006) Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 113: 647-656. doi:10.1161/CIRCULATIONAHA.105.552737. PubMed: 16461837.